glp-1 kidney outcomes news today Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis - Jorge - 2026 - Arthritis & Rheumatology Cardiovascular, Kidney, and Safety Outcomes

These neurons send widespread projections to brain regions that highly express GLP-1Rs [66, 69], where administration of GLP-1R agonists reduces food intake and GLP-1R antagonists increase food intake such as the bed nucleus of the stria terminalis (BNST) as a notable example [70] (Fig

Nearly one in eight adults now reports taking a GLP-1 for weight loss or chronic condition management

Patients should be empowered as active participants in treatment decisions, with ongoing dialogue about benefits, risks, and treatment goals tailored to their individual circumstances

Special thanks are also extended to the Comprehensive Research Laboratory and the Center for Breeding and Cultivation of Laboratory Animals at the Jiroft University of Medical Sciences for their invaluable resources and assistance throughout this research

This is covered in detail in the maintenance section, but briefly: people who have established ketogenic metabolic adaptation while on semaglutide appear better positioned to maintain their weight loss after discontinuation than people who relied purely on drug-mediated appetite suppression